Novo Nordisk Expands Wegovy Reach and Reports Record FY25 Profits

Key Facts

1Novo Nordisk ended its dispute with Hims & Hers Health, enabling Wegovy distribution across a platform with 2.5 million subscribers.

2The company achieved a net profit of DKK 100 billion in FY25 with a gross margin of 82.41%.

3Operating cash flow approached DKK 120 billion, supporting CapEx and acquisitions.

Novo Nordisk has successfully resolved its dispute with Hims & Hers Health, marking a significant strategic move to expand the distribution of its weight-loss drug, Wegovy. This settlement allows Wegovy to be offered across a platform with over 2.5 million subscribers, significantly broadening the company's market reach. On the financial front, the pharmaceutical giant reported a robust net profit of DKK 100 billion for the 2025 fiscal year. The company's operational efficiency was highlighted by an impressive gross margin of 82.41%, reflecting its dominant position in the GLP-1 sector. Furthermore, operating cash flow approached DKK 120 billion, providing substantial liquidity for future capital expenditures and strategic acquisitions. These developments underscore Novo Nordisk's strong fundamental growth and its ability to navigate complex distribution landscapes.